Salim, H. M., Fukuda, D., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016). Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Front Cardiovasc Med.
Citação norma ChicagoSalim, Hotimah Masdan, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro, and Masataka Sata. "Glycemic Control With Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse." Front Cardiovasc Med 2016.
ציטוט MLASalim, Hotimah Masdan, et al. "Glycemic Control With Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse." Front Cardiovasc Med 2016.